- Published on Friday, 18 May 2012 21:12
The University of Texas at El Paso and Premier Biomedical, Inc. (OTCBB:"BIEI") have signed a collaboration agreement to conduct joint research of Premier’s sequential-dialysis technique, a method for the removal of harmful molecules that cause diseases.
The research projects will use Premier Biomedical, Inc's. patent-pending technology to "Remove the Pathophysiologic Basis of the Disease"™ developed by its co-founder, Dr. Mitchell S. Felder.
The team will concentrate initially on developing treatments for traumatic brain injury, cancer, and Alzheimer's disease, said Robert Kirken, Ph.D., professor and chair of biological sciences at UTEP.
“The goal is to try to remove unwanted proteins or molecules that exacerbate or cause the disease state,” Kirken said. “With UTEP’s technology, coupled with the support of Premier Biomedical, we may be able to address these human diseases.”
Researchers in UTEP’s $45 million state-of-the-art Border Biomedical Research Center (BBRC) will test Premier’s patents inside the BBRC’s six core laboratories, which allow faculty to conduct vital research using advanced technology.
- The Analytical Cytology lab provides UTEP scientists with advanced instrumentation to study cell structure, function and disease state.
- The Bioinformatics Computing lab offers high performance computing capabilities to support computer modeling and database development.
- The Cell Culture and High Throughput Screening (HTS) Core lab is a comprehensive research facility that provides investigators with advanced technology to conduct cell-based experiments and test a large number of compounds against cancer, pathogens, and other diseases.
- The DNA Analysis Core Facility supports UTEP researchers in their nucleic acid-based research studies such as sequencing, typing and fingerprinting.
- The Statistical Consulting Lab provides BBRC faculty with statistical and computing support.
- Biomolecule Analysis lab supports scientists by specializing in the separation and characterization of biomolecules.
"The agreement with UTEP offers an optimum synergistic relationship where the vast intellectual capabilities of the University will facilitate more rapid product development and reduce time-to-market for our technology,” said William A. Hartman, President, CEO, and co-founder of Premier Biomedical, Inc. “Using the University’s facilities to conduct the necessary research on our initial products is a tremendous benefit to this company and its shareholders. The initial focus of the team on traumatic brain injury, cancer, and Alzheimer's disease has immediate potential to finally develop a badly needed cure for these dreaded diseases for all humanity."
UTEP graduate and undergraduate students also will be trained in these new therapeutic strategies to help fight and combat human disease, helping to boost UTEP’s bid to become a national research university with a 21st century demographic.
Established in 1992, with support from the Research Centers in Minority Institutions (RCM) and the National Institutes of Minority Health Disparities (NIMHD), the BBRC addresses health issues relevant to the population along the U.S.-Mexico border.
Premier Biomedical, Inc. is located in Port Richey, Fla. and also has operations in Jackson Center, Penn. More information about Premier Biomedical, Inc. and its revolutionary technology can be found on the company’s web site at www.premierbiomedicalinc.com.